生物标志物的发现和验证：统计考虑。
Biomarker Discovery and Validation: Statistical Considerations.
机构信息
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Department of Biostatistics and Epidemiology, Gustave Roussy, Oncostat U1018, CESP, Inserm, Université Paris-Saclay, labelel Ligue Contre le Cancer, Villejuif, France.
出版信息
J Thorac Oncol. 2021 Apr;16(4):537-545. doi: 10.1016/j.jtho.2021.01.1616. Epub 2021 Feb 2.
Abstract
Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making is more important than ever. In this article, we discuss best the practices and potential issues in biomarker discovery and validation. We encourage team science partnerships to bring cutting-edge discovery from bench to bedside, leading to improved patient care and outcomes.
摘要
生物标志物有多种应用，包括疾病检测、诊断、预后、干预反应预测和疾病监测。在精准医学时代，拥有经过验证的生物标志物来为临床决策提供信息比以往任何时候都更加重要。在本文中，我们讨论了生物标志物发现和验证的最佳实践和潜在问题。我们鼓励团队科学合作，将前沿发现从实验室带到床边，从而改善患者的护理和结局。
相似文献
1
Biomarker Discovery and Validation: Statistical Considerations.生物标志物的发现和验证：统计考虑。
J Thorac Oncol. 2021 Apr;16(4):537-545. doi: 10.1016/j.jtho.2021.01.1616. Epub 2021 Feb 2.
2
Biomarkers: Delivering on the expectation of molecularly driven, quantitative health.生物标志物：实现分子驱动、定量健康的期望。
Exp Biol Med (Maywood). 2018 Feb;243(3):313-322. doi: 10.1177/1535370217744775. Epub 2017 Dec 3.
3
Biomarker development in the precision medicine era: lung cancer as a case study.精准医学时代的生物标志物开发：以肺癌为例
Nat Rev Cancer. 2016 Aug;16(8):525-37. doi: 10.1038/nrc.2016.56. Epub 2016 Jul 8.
4
Statistical consideration for clinical biomarker research in bladder cancer.膀胱癌临床生物标志物研究的统计学考虑。
Urol Oncol. 2010 Jul-Aug;28(4):389-400. doi: 10.1016/j.urolonc.2010.02.011.
5
Unbiased data analytic strategies to improve biomarker discovery in precision medicine.无偏数据分析策略可提高精准医学中的生物标志物发现。
Drug Discov Today. 2019 Sep;24(9):1735-1748. doi: 10.1016/j.drudis.2019.05.018. Epub 2019 May 31.
6
Translation of Precision Medicine Research Into Biomarker-Informed Care in Radiation Oncology.精准医学研究向放射肿瘤学中基于生物标志物的护理的转化。
Semin Radiat Oncol. 2022 Jan;32(1):42-53. doi: 10.1016/j.semradonc.2021.09.001.
7
Computer-aided biomarker discovery for precision medicine: data resources, models and applications.计算机辅助精准医学生物标志物发现：数据资源、模型和应用。
Brief Bioinform. 2019 May 21;20(3):952-975. doi: 10.1093/bib/bbx158.
8
Biomarkers in pediatrics: children as biomarker orphans.儿科生物标志物：被遗忘的儿童生物标志物。
Proteomics Clin Appl. 2010 Dec;4(12):915-21. doi: 10.1002/prca.201000062.
9
Biomarkers as drug development tools: discovery, validation, qualification and use.生物标志物作为药物研发工具：发现、验证、确证和应用。
Nat Rev Rheumatol. 2018 Jun;14(6):354-362. doi: 10.1038/s41584-018-0005-9.
10
Translational bioinformatics and data science for biomarker discovery in mental health: an analytical review.精神健康生物标志物发现的转化生物信息学和数据科学：分析综述。
Brief Bioinform. 2024 Jan 22;25(2). doi: 10.1093/bib/bbae098.
引用本文的文献
1
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8 and PD-1 Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors.机构规模的免疫谱分析表明，肿瘤内大量的CD8和PD-1细胞预示着主要癌症类型患者的生存情况更好，且不受主要风险因素的影响。
JCO Precis Oncol. 2025 Sep;9:e2500240. doi: 10.1200/PO-25-00240. Epub 2025 Sep 4.
2
From Natriuretic Peptides to microRNAs: Multi-Analyte Liquid Biopsy Horizons in Heart Failure.从利钠肽到微小RNA：心力衰竭中的多分析物液体活检前景
Biomolecules. 2025 Aug 19;15(8):1189. doi: 10.3390/biom15081189.
3
Pleural fluid biomarkers to predict response to pleurodesis or indwelling pleural catheter for malignant pleural effusion: still a long way to go.预测恶性胸腔积液对胸膜固定术或留置胸腔导管反应的胸腔积液生物标志物：仍有很长的路要走。
Respir Res. 2025 Aug 20;26(1):259. doi: 10.1186/s12931-025-03288-5.
4
Recent Advances in Micro- and Nano-Enhanced Intravascular Biosensors for Real-Time Monitoring, Early Disease Diagnosis, and Drug Therapy Monitoring.用于实时监测、疾病早期诊断和药物治疗监测的微纳增强型血管内生物传感器的最新进展
Sensors (Basel). 2025 Aug 7;25(15):4855. doi: 10.3390/s25154855.
5
Epitranscriptomic alterations induced by environmental toxins: implications for RNA modifications and disease.环境毒素诱导的表观转录组改变：对RNA修饰和疾病的影响。
Genes Environ. 2025 Aug 4;47(1):14. doi: 10.1186/s41021-025-00337-9.
6
The prognostic and predictive value of peripheral immune-related proteins in patients with lung cancer treated with radiotherapy.外周免疫相关蛋白在接受放疗的肺癌患者中的预后及预测价值
Front Oncol. 2025 Jul 17;15:1625212. doi: 10.3389/fonc.2025.1625212. eCollection 2025.
7
lncRNAs as Biomarkers of Hepatocellular Carcinoma Risk and Liver Damage in Advanced Chronic Hepatitis C.长链非编码RNA作为晚期慢性丙型肝炎肝细胞癌风险和肝损伤的生物标志物
Curr Issues Mol Biol. 2025 May 10;47(5):348. doi: 10.3390/cimb47050348.
8
CoxKAN: Kolmogorov-Arnold networks for interpretable, high-performance survival analysis.CoxKAN：用于可解释的高性能生存分析的柯尔莫哥洛夫 - 阿诺德网络
Bioinformatics. 2025 Aug 2;41(8). doi: 10.1093/bioinformatics/btaf413.
9
Current Bioinformatics Tools in Precision Oncology.精准肿瘤学中的当前生物信息学工具
MedComm (2020). 2025 Jul 9;6(7):e70243. doi: 10.1002/mco2.70243. eCollection 2025 Jul.
10
Towards early detection and disease interception of COPD across the lifespan.实现慢性阻塞性肺疾病（COPD）全生命周期的早期检测与疾病阻断。
Eur Respir Rev. 2025 Jul 9;34(177). doi: 10.1183/16000617.0243-2024. Print 2025 Jul.
本文引用的文献
1
2020 ASCO Virtual Annual Meeting.2020年美国临床肿瘤学会虚拟年会
Lancet Oncol. 2020 Jul;21(7):885-886. doi: 10.1016/S1470-2045(20)30313-2. Epub 2020 Jun 5.
2
and mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort.并在观察性真实世界肺腺癌队列中作为预后生物标志物的突变。
ESMO Open. 2020 Apr;5(2). doi: 10.1136/esmoopen-2020-000706.
3
Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies.通过案例研究讨论用于生物标志物识别与验证的试验设计
JCO Precis Oncol. 2019;3. doi: 10.1200/po.19.00051. Epub 2019 Oct 24.
4
EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.EURACAN/IASLC 提出更新胸膜间皮瘤组织学分类的建议：采用更具多学科性的方法。
J Thorac Oncol. 2020 Jan;15(1):29-49. doi: 10.1016/j.jtho.2019.08.2506. Epub 2019 Sep 20.
5
Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.晚期非小细胞肺癌：2018 年胸部肿瘤学进展。
J Thorac Oncol. 2019 Jul;14(7):1134-1155. doi: 10.1016/j.jtho.2019.03.022. Epub 2019 Apr 16.
6
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.美国食品药品监督管理局批准摘要：帕博利珠单抗用于治疗微卫星高度不稳定实体瘤。
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758. doi: 10.1158/1078-0432.CCR-18-4070. Epub 2019 Feb 20.
7
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.FDA 批准帕博利珠单抗用于生物标志物定义的疾病的意义和影响。
J Immunother Cancer. 2018 May 14;6(1):35. doi: 10.1186/s40425-018-0342-x.
8
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.西妥昔单抗联合卡铂和紫杉醇与卡铂和紫杉醇联合或不联合贝伐珠单抗治疗晚期 NSCLC（SWOG S0819）：一项随机、3 期研究。
Lancet Oncol. 2018 Jan;19(1):101-114. doi: 10.1016/S1470-2045(17)30694-0. Epub 2017 Nov 20.
9
Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.STK11突变在非鳞状非小细胞肺癌中的不同预后影响。
Oncotarget. 2017 Apr 4;8(14):23831-23840. doi: 10.18632/oncotarget.6379.
10
Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools.肺癌预后的优化：临床预后工具的质量与相关性报告
J Thorac Oncol. 2015 Nov;10(11):1576-89. doi: 10.1097/JTO.0000000000000652.
Zotero 插件